This morning, executives from Beckley Psytech and atai Life Sciences hosted a conference call to discuss the topline results from their Phase 2b study of intranasal 5-MeO-DMT (BPL-003) for treatment-resistant depression (TRD). On the call, atai CEO Srini Rao said that the results “exceeded all our expectations”, and Beckley CEO Cosmo Feilding-Mellen went on to share his excitement around the…
